Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

. Author manuscript; available in PMC: 2019 Oct 29.
Published in final edited form as: Clin Cancer Res. 2017 Sep 14;23(22):7047–7058. doi: 10.1158/1078-0432.CCR-17-0077

Figure 3. MSC-mIFNβ show antitumor efficacy in resected GBM, leading to increased survival of mice and can be eliminated post-therapy:

Figure 3.

(A) Representative BLIs and plot of mean Fluc signal intensity of mice bearing intracranial MSC-GFP-Fluc cells with or without sECM encapsulation (1 × 106 cells/mouse, n=4/group) (B) Schematic and fluorescence images showing MSC-GFP or MSC-mIFNβ cells encapsulated in sECM (1 × 104 cells/drop), surrounded by CT2A-FmC cells. Plot showing CT2A cell viability at day5 (C) Scheme for testing efficacy of sECM-encapsulated MSCs expressing GFP or mIFNβ on resected CT2A-FmC tumors (n=6/group): (i) Light image of a craniotomy above tumor, delineated by dashed black circle. (ii, iii) Fluorescence images of before-resected CT2A-FmC tumor (red) and encapsulated MSC-mIFNβ cells in the resection cavity (green). (D) Representative BLIs of mice from MSC-GFP and -mIFNβ groups pre- and post-resection, plot of mean tumor growth and (E) survival curves. (F-G) Resected mice were implanted with sECM-encapsulated MSC-mIFNβ-TK-Fluc (n=6) and treated with GCV (50 mg/kg) or PBS daily for 5 days. (F) Representative BLIs of mice at 1, 3 and 5 days post-GCV treatment and plot of mean tumor growth (G) Light and fluorescence micrographs of coronal brain sections containing encapsulated MSC-mIFNβ-TK-Fluc (green) from brains harvested 7 days post-GCV treatment and DAPI counterstained (blue). White dashed box indicates region of interest. Scale bar 100 μm.

HHS Vulnerability Disclosure